WHAT WE DO

The existing brand value proposition proved cumbersome, resulting in suboptimal user and audience experience. We designed new information architecture that supports scenario-based storytelling, enabling account managers to deliver a clear, succinct value narrative. This user-focused "choose your own adventure" tool now drives meaningful engagements and has the highest utilization of access marketing assets.

Market pricing pressures and biosimilar erosion created a need for lower-cost therapy. We developed a simple, clear, and consistent narrative to ensure various stakeholders understood the role of the branded biologic. Targeted audience messaging and engagement helped secure coverage for approximately 30 million lives through large payers.

A rare disease affecting children with debilitating itch, often leading to liver transplant, led to significant costs with no FDA-approved treatments. We educated payers by defining the clinical, economic, and emotional burden of the disease. Through a compelling value story, we secured coverage on several regional and national plans within the first few months of launch, ultimately achieving 100% coverage within one year.

In a mature market with entrenched standard of care and reluctance for early use of newer therapies, a launching multiple sclerosis product faced several access hurdles. From pre-approval information exchange engagements to post-launch pull-through, we established a clear unmet needs platform and nuanced value narrative across key stakeholders. This resulted in day 1 coverage with top plans and PBMs, meeting market access goals 3 months post-launch.

To disrupt a stagnant and satisfied heart failure market that did not perceive unmet needs, we partnered with an actuarial consultancy to quantify cost of care in this category. Leveraging claims-based burden evidence combined with clinical and economic data, an innovative pre-launch campaign demonstrated burden of disease to payers and health systems, upending a generic market. The successful launch established a new standard of care in heart failure.

Healthcare providers incorrectly believed competitor products to treat rheumatoid arthritis had better access. We launched a comprehensive pull-through campaign that raised awareness of the product's first-line formulary coverage and reinforced its place in the treatment continuum. The campaign reached more than 10,000 providers, fueling the product to reach its highest market share in brand history.